ORCiD numbers: 0000-0002-5547-5084 (E. D. Michos).
C onsiderable differences exist in the prevalence and manifestation of atherosclerotic cardiovascular disease (CVD) and heart failure (HF) between men and women (1, 2) . Premenopausal women have a lower risk of CVD and HF compared with men; however, this risk increases after menopause (3) (4) (5) . Sex hormones, particularly androgens, are associated with CVD risk factors and events and have been postulated to mediate the observed sex differences in CVD (6) (7) (8) (9) (10) .
B-type natriuretic peptides (BNPs) are secreted from cardiomyocytes in response to myocardial wall stress (11) . BNP plays an important role in cardiovascular remodeling and volume homeostasis. It exerts numerous cardioprotective effects by promoting vasodilation, natriuresis, and ventricular relaxation and by antagonizing fibrosis and the effects of the renin-angiotensin-aldosterone system (11) . Although the physiological role of BNP is cardioprotective, pathologically elevated N-terminal pro-BNP (NT-proBNP) levels are used clinically to indicate left ventricular hypertrophy, dysfunction, and myocardial ischemia (12) (13) (14) (15) . Higher NT-proBNP levels among individuals free of clinical CVD are associated with an increased risk of incident CVD (16) , HF (17) , and cardiovascular mortality (18, 19) .
BNP and NT-proBNP levels are higher in women than men in the general population (20) (21) (22) . Several studies have proposed the use of sex-and age-specific reference ranges for BNP and NT-proBNP levels, in which reference limits are higher for women and older individuals (20, 21, 23, 24) . The etiology behind this sex difference has not been fully elucidated, but prior studies have demonstrated an association between sex hormones and NT-proBNP levels. Analyzing the relationship between NT-proBNP and sex hormones may help clarify the role of sex hormones in CVD/HF pathogenesis. Current data on the exact associations between BNP and sex hormones are controversial. Initial studies, particularly in women using estrogen therapy, have proposed that estrogen may have a stimulating effect on the natriuretic peptide (NP) system (20, (25) (26) (27) . More recent studies measuring endogenous sex hormones have suggested that androgens may play a larger role in BNP regulation by inhibiting its production (28, 29) . These studies are predominantly cross-sectional and limited in the number of sex hormones measured. Additionally, the association between sex hormone levels and change in NT-proBNP levels over time is unknown. Therefore, to address these knowledge gaps, we used data from a large, multiethnic community-based cohort of individuals free of CVD and HF at baseline to analyze both the cross-sectional and longitudinal associations between sex hormones [total testosterone (T), bioavailable T, free T, dehydroepiandrosterone (DHEA), SHBG, and estradiol] and NT-proBNP, separately for women and men. We hypothesized that a more androgenic profile of sex hormones would be inversely associated with NT-proBNP levels in both cross-sectional and longitudinal analyses and that the associations would be stronger in women than in men.
Materials and Methods

Data availability statement
The Multi-Ethnic Study of Atherosclerosis (MESA) cohort participates in the National Heart, Lung, and Blood Institute's Biologic Specimen and Data Repository (BioLINCC). The MESA data are available upon request, including data from examinations 1 to 5 used in this analysis. Requests for data can be made through the following Web site: https://biolincc.nhlbi. nih.gov/studies/mesa/.
Study population
The MESA is a prospective community-based cohort study investigating the characteristics of subclinical CVD and its progression into clinical CVD. It enrolled 6814 men and women of 4 self-reported race/ethnicities (white, black, Hispanic, and Chinese American), who were 45 to 84 years old at the time of the baseline examination (2000 to 2002) (30) . MESA participants were recruited at six centers across the United States and were free of CVD/HF at baseline. The study was approved by the institutional review boards of all participating institutions, and all participants provided written informed consent.
Our study included cross-sectional and longitudinal analyses (Fig. 1) . Premenopausal women (n = 514) were excluded, as sex hormone levels differ significantly between premenopausal and Figure 1 . Selection of study sample. doi: 10.1210/jc.2018-01437 https://academic.oup.com/jcem 4305 postmenopausal women. Participants with missing data for sex hormones (n = 209), baseline NT-proBNP (n = 975), and covariates from our second model (n = 57), described later, were also excluded. Ultimately, 5059 participants were included in the cross-sectional analysis. Of this sample, those that had at least one repeat measure of NT-proBNP at examination 3 (2004 to 2005) and/or examination 5 (2010 to 2012) were included in our longitudinal analysis (n = 4389).
Measurement of sex hormones
Early morning fasting blood samples were collected and stored at 270°C at the time of the baseline examination (examination 1). Sex hormones were measured from stored serum samples at the Steroid Hormone Laboratory at the University of Massachusetts Medical Center (Worcester, MA). Ultrasensitive radioimmunoassay kits from Diagnostic System Laboratories (Webster, TX) were used to measure estradiol. Total T and DHEA were measured using radioimmunoassay kits, and SHBG was measured via a chemiluminescence enzyme immunometric assay using Immulite kits from Diagnostic Products Corporation (Los Angeles, CA). Bioavailable T and free T were calculated using total T and SHBG concentrations by equations described by Sodergard et al. (31) Intra-assay coefficients of variation for estradiol, total T, DHEA, and SHBG were 10.5%, 12.3%, 11.2%, and 9.0%, respectively.
Measurement of NT-proBNP
NT-proBNP levels were measured from blood samples that were collected at the time of examinations 1, 3, and 5 and stored at 270°C. NT-proBNP measurements from a subset of examination 1 and 3 participants, plus participants at examination 5, were performed using the Elecsys proBNP immunoassay (Roche Diagnostics Corporation, Indianapolis, IN) at the University of California San Diego and the University of Vermont (32) . Additional measures of NT-proBNP were performed in the remaining samples from examinations 1 and 3 using the Cobas e601 (Roche Diagnostics Corporation) at the University of Maryland (33) . NT-proBNP assays were harmonized across different Roche platforms. The measurement range was 5 to 35,000 pg/mL, and the intra-assay and interassay coefficients of variation were as follows: 2.7% and 3.2% at 175 pg/mL, 2.4% and 2.9% at 355 pg/mL, 1.9% and 2.6% at 1068 pg/mL, and 1.8% and 2.3% at 4962 pg/mL (32) .
Measurement of other covariates
Sociodemographic and lifestyle characteristics, as well as CVD risk factors, were obtained at examination 1 using standardized questionnaires, physical examination, and laboratory measures as described previously (30) . Physical activity was defined as the total amount of moderate plus vigorous intentional exercise performed in a usual week and summed as metabolic equivalent minutes per week. Menopausal status was determined from a combination of self-reported status, age, age of menopause, and history of hysterectomy or oophorectomy (34) . Due to missing self-reported menopausal status data, as well as inconsistencies within the data, an algorithm was created to more accurately delineate the sample of postmenopausal women [shown in an online repository (35) ]. Participants were deemed postmenopausal if they met one or more of the following criteria: (1) age $55 years (86% of cross-sectional sample); (2) age ,55 years without history of hysterectomy with available menopause age data (10%); (3) age ,55 years with self-reported postmenopausal status, but no menopause age data, without history of hysterectomy (0.04%); (4) age ,55 years with history of hysterectomy and bilateral oophorectomy if not already deemed postmenopausal by any previous criteria (4%); and (5) age ,55 years with history of hysterectomy without bilateral oophorectomy with reported hysterectomy at age older than menopause age (0.08%). As stated previously, only postmenopausal women were included in this analysis.
Body mass index (BMI) was calculated by weight (kilograms) divided by height (meters) squared. Seated blood pressure was measured using a Dinamap automated oscillometric sphygmomanometer (GE Critikon, Tampa, FL). Hypertension was defined as systolic blood pressure (SBP) $140 mm Hg, diastolic blood pressure $90 mm Hg, or treatment with antihypertensive medication. Diabetes was defined as a fasting glucose $126 mg/dL, self-reported diagnosis of diabetes, or treatment with hypoglycemic medications. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (36) .
Statistical analysis
All analyses were performed stratified by sex, because sex hormone levels differ significantly between women and men, with nonoverlapping distributions. Continuous variables were summarized as means (SD) or medians (interquartile range) in the case of skewed distributions. Categorical variables were expressed as percentages.
Cross-sectional and longitudinal associations between sex hormones and NT-proBNP were determined using multivariableadjusted linear mixed-effects models. Because sex hormone and NT-proBNP distributions were skewed, we used log-transformed values for both. Sex hormones were modeled individually as continuous measures, and the 90th vs 10th percentiles of their logtransformed distributions were compared for contrast. For NTproBNP, participants could contribute two or three data points for longitudinal analyses. Among our sample, 3085 participants had all three data points (examinations 1, 3, and 5), and 1304 participants had data at examination 1 plus one follow-up measurement at either examination 3 or 5. Cross-sectional associations were represented by coefficients of the sex hormones, which estimate the difference in NT-proBNP at baseline by varying sex hormone levels. Longitudinal associations were represented by coefficients of interactions between sex hormones and time since baseline, which estimate the rate of change in NTproBNP associated with sex hormones. The longitudinal analyses adjusted for baseline NT-proBNP values in the mixed-effects models. Because log-transformed values of sex hormones and NT-proBNP may be difficult to interpret, the beta coefficients from the linear mixed-effects models were then exponentiated and presented as ratios (95% CI) of the NT-proBNP geometric means.
We used three models that were progressively adjusted for potential confounders. Model 1 adjusted for demographic factors, including age, race/ethnicity, and MESA site. Model 2 included all covariates in model 1, plus lifestyle, socioeconomic, body composition, and hormonal factors, including education, smoking, alcohol consumption, BMI, and physical activity, as well as use of hormone therapy (HT) and years since menopause in women. Model 3 included all covariates of model 2, plus CVD risk factors, including diabetes, SBP, use of antihypertensive medications, total and high-density lipoprotein (HDL) cholesterol, use of lipid-lowering therapy, and eGFR.
We additionally modeled sex hormones continuously using restricted cubic splines (with knots at the 5th, 35th, 65th, and 95th percentiles of the sex hormone sample distributions) to assess for potential nonlinearity and to model a flexible doseresponse relationship between sex hormones and NT-proBNP. Sensitivity analyses were performed to exclude women on HT at baseline, participants with reduced left ventricular ejection fraction (LVEF) at baseline (defined as ,50% as assessed by cardiac MRI), and participants with incident clinical CVD events between examinations 1 and 5. Given inherent interest in differences by race/ethnicity in this multiethnic cohort, results were also stratified by race/ethnic groups in exploratory analyses.
Two-sided P values ,0.05 were considered statistically significant. All analyses were performed on STATA version 14 (StataCorp LP, College Station, TX).
Results
Participant characteristics
Baseline characteristics of the cross-sectional sample (n = 5059), stratified by sex, are shown in Table 1 . Women were slightly older than men (mean age 65.1 and 62.3 years, respectively). NT-proBNP levels were higher in women than men at baseline (median 79.9 and 38.5 pg/mL, respectively). Women had higher BMI, participated in less physical activity, and were less likely to be smokers than men. Women also had higher SBP and total cholesterol and were less likely to have diabetes. Approximately one-third (32.9%) of women were receiving HT. Baseline characteristics of the longitudinal subsample (n = 4389) are presented in an online repository (35) and are similar to those of the cross-sectional sample.
Cross-sectional analysis Table 2 shows the adjusted cross-sectional associations between baseline sex hormones and baseline levels of NT-proBNP. Among women, higher total T, bioavailable T, free T, and DHEA levels were independently associated with lower NT-proBNP (model 1). These inverse associations remained noteworthy after further adjusting for lifestyle factors and hormonal status (model 2) and for other CVD risk factors (model 3). The 12 to 1.21) ]. These results were also generally consistent after stratifying by race/ethnicity (35) . Table 3 shows the association between baseline sex hormones and adjusted change in NT-proBNP over a 10- All aforementioned associations in women were preserved after excluding 22 women with reduced LVEF at baseline (35) . After excluding 691 women who were receiving HT at baseline, bioavailable T, free T, and estradiol levels were associated with greater longitudinal increase in NT-proBNP, and SHBG levels were associated with less change in NT-proBNP (35) . The pattern of findings also remained consistent after excluding 116 women with incident CVD and HF events during follow-up (35) as well as after stratifying by race/ ethnicity (35) .
Longitudinal analysis
In men, greater free T and estradiol were associated with a greater increase in NT-proBNP over 10 years (Table 3) , even after adjusting for demographic, lifestyle, and CVD risk factors (model 3). The adjusted ratios were 1.04 (1.00 to 1.09) for free T and 1.08 [1.03 to 1.13] for estradiol. Findings were consistent after excluding 57 men with reduced LVEF at baseline (35) , after excluding 197 men with incident CVD and HF during follow-up (35) , and after stratifying by race/ethnicity (35) .
To test for a nonlinear relationship between sex hormones and NT-proBNP, we modeled the associations using adjusted restricted cubic splines (Figs. 2 and 3) . Among women, those with free T in the 10th percentile had higher baseline NT-proBNP levels than those with free T in the 90th percentile ( Fig. 2A ; time = 0 years). However, notably, the longitudinal increase and slope of the rise in NT-proBNP was greater among women with the highest free T. Despite having lower NT-proBNP levels at baseline, women with free T in the 90th percentile had a steeper increase in their NT-proBNP levels such that their NT-proBNP levels were not significantly different from those in women with free T in the 10th percentile by the end of follow-up ( Fig. 2A ; time = 11 years). In terms of estradiol, the differences in baseline and longitudinal NT-proBNP levels in women with 10th percentile compared with 90th percentile estradiol levels were not statistically noteworthy (Fig. 3A) . Among men, those with baseline free T in the 10th percentile had higher NT-proBNP levels over the course of follow-up than those with free T in the 90th percentile (Fig. 2B) . Men with estradiol in the 90th percentile had lower NT-proBNP levels at baseline, but had greater increase in their NT-proBNP levels such that over the course of follow-up, their NT-proBNP levels were similar to that of men with estradiol in the 10th percentile (Fig. 3B) .
We additionally examined the associations of sex (women vs men) with baseline and longitudinal change in NT-proBNP levels (Table 4) . After adjusting for demographic and lifestyle covariates and CVD risk factors, women had greater adjusted geometric means of NTproBNP levels at baseline [women: 68.1 pg/mL (65.5 to 70.9); men: 39.7 (38.3 to 41.2)], but men demonstrated a greater increase in NT-proBNP levels over the 10-year 14 (1.10, 1.19) 1.13 (1.09, 1.18) 1.13 (1.09, 1.18 
Discussion
In a large, multiethnic cohort of men and women free of baseline clinical CVD/HF, we found that women had higher levels of NT-proBNP at baseline, but men had a greater increase in NT-proBNP over 10 years of followup, after accounting for age and CVD risk factors. Additionally, we found that a more androgenic pattern of sex hormones (higher bioavailable T, free T, and DHEA, and lower SHBG) was associated with lower baseline NT-proBNP levels in men and postmenopausal women. These cross-sectional associations suggest a potential mechanism for the higher levels of NT-proBNP observed in women compared with men, seen in our study and in other studies in the general population (20) (21) (22) . Unexpectedly, we found that the longitudinal associations between sex hormones and change in NT-proBNP were the opposite of their cross-sectional associations. In women, a more androgenic and less estrogenic pattern of sex hormones (higher total T, bioavailable T, free T, and DHEA and lower SHBG and estradiol) were positively associated with change in NT-proBNP levels over 10 years. In men, higher estradiol and higher free T levels were associated with greater increase in NT-proBNP. Fewer sex hormones demonstrated statistically significant longitudinal associations with NT-proBNP in men than in women, suggesting that the relationship between sex hormones and change in NT-proBNP may be more robust in women compared with men. Overall, our results show that although women with a more androgenic pattern of sex hormones have lower NT-proBNP levels at baseline, they also experience a greater increase in NT-proBNP over time.
Cross-sectional vs longitudinal associations between sex hormones and NT-proBNP NT-proBNP mediates various cardioprotective effects by stimulating vasodilation and natriuresis and inhibiting hypertrophy and fibrosis. States of NP deficiency, including obesity and African-American race, have been associated with adverse cardiovascular outcomes, including hypertension and HF (37) (38) (39) . Our cross-sectional analyses demonstrated that a more androgenic pattern of sex hormones was associated with lower levels of NT-proBNP in women and men, suggesting that having a more androgenic pattern of sex hormones may represent another state of NP deficiency. This may contribute the rise in CVD/HF risk in women after menopause, when women experience a decrease in estrogens and develop relative androgen excess. To our knowledge, the longitudinal relationship between sex hormones and NT-proBNP has not been previously studied. Our analysis showed that, in women, a more androgenic pattern of sex hormones was associated with a greater increase in NT-proBNP over time. This was consistent with our finding that men experienced a greater longitudinal change in NT-proBNP levels than women. Although NT-proBNP plays a favorable role in cardioprotective and homeostatic functions, elevated levels of NT-proBNP are seen in acute HF and acute coronary syndrome and used clinically as markers of pathology. Studies have suggested that patients with HF demonstrate BNP resistance and suffer from relative BNP deficiency, resulting in activation of compensatory systems that increase BNP levels to restore homeostasis (11) . In acute HF, BNP undergoes abnormal processing into less biologically active forms that are indistinguishable from active forms on standard assays. As a consequence, patients with HF experience blunted physiological effects of BNP, despite having significantly elevated NT-proBNP values (40, 41) . A prior MESA found that the inverse relationship between NT-proBNP and various CVD risk factors, including BMI, lipids, and insulin resistance, was present at NT-proBNP levels ,100 pg/mL, but not present at levels $100 pg/mL (42) .
Taken together, current evidence suggests that although NT-proBNP exerts cardioprotective effects to maintain volume homeostasis and states of NP deficiency are associated with higher risk of CVD, elevated levels of NT-proBNP predict poorer outcomes. The apparently paradoxical roles of NT-proBNP as both a cardioprotective hormone and a biomarker of CVD and HF are likely due to the involvement of NT-proBNP in a negative-feedback loop, in which there is a compensatory increase in NT-proBNP levels in the setting of pathology (39) . In our study, at baseline, a more androgenic pattern of sex hormones was associated with lower NT-proBNP, which may represent a state of NP deficiency. Over the course of follow-up, a more androgenic and less estrogenic pattern of sex hormones was associated with greater change in NT-proBNP. Women with the highest percentile of free T had the lowest levels of NT-proBNP at baseline but had the greatest increase in NT-proBNP over time. The rise in NT-proBNP over time in these women may reflect the development of incident subclinical CVD and subsequent compensatory increase in NT-proBNP levels, particularly in those with relative NP deficiency at baseline. The association between androgenic sex hormones and greater change in NT-proBNP may also help explain the higher incidence of CVD in men and postmenopausal women compared with premenopausal women, who have relatively lower androgen levels. Additionally, our results suggest that higher levels of androgenic hormones may identify individuals who may have greater CVD risk.
Our findings also suggest that the associations of androgens with NT-proBNP levels are more robust in women than in men, which was previously unrecognized. This suggests that sex hormone levels may affect change in NT-proBNP in women more so than in men, which mirrors the increase in the risk of HF with preserved ejection fraction (HFpEF) in women compared with men.
Role of androgens vs estrogen in NP regulation
Whether the suppressive effect of androgens or the stimulatory effect of estrogens is the primary driver in sex hormone regulation of BNP is unclear, as there is evidence for both from prior studies. A study of men with systolic HF demonstrated that total and free T were inversely associated with NT-proBNP (43) . In women, higher androgens have been found to be associated with lower NT-proBNP, whereas estrogen status did not affect NT-proBNP levels (28, 29, 44) . A cross-sectional analysis of premenopausal women in the Dallas Heart Study found that higher levels of SHBG and lower levels of T were correlated with higher BNP and NT-proBNP levels (28) . Additionally, the Framingham Heart Study showed that higher SHBG and lower free T were associated with higher NT-proBNP in both women and men crosssectionally (29) . These prior studies have proposed that men may have an NP deficiency compared with women. Our cross-sectional results extend these findings by showing that higher androgen levels were associated with lower NT-proBNP in women and men across a range of androgenic sex hormones. Our results also suggest that a more androgenic sex hormone pattern may mediate the state of NP deficiency in both men and women.
In terms of estrogen modulation of the NP system, NP levels have been found across multiple studies to be higher in women using HT compared with those not on HT (20, 26, 27, 45) . However, other studies have argued that estrogen is not primarily responsible for sex differences in BNP (28, 29, 44) . Of note, many of these studies were limited by the inability to measure endogenous estrogen levels in both men and women, and estrogen status in women was inferred from menopausal status, HT use, and measurement of other hormones in the gonadal axis.
Our ability to measure estradiol directly in both men and women allows us to discern the differences in the relationship between estradiol and NT-proBNP in men and women, after adjustment for important clinical confounders. Our study demonstrates that, among women, only androgens, not estrogen, were associated with NT-proBNP in cross-sectional analyses. This supports the hypothesis that primarily androgens, rather than estrogens, influence cross-sectional NT-proBNP levels in postmenopausal women. Of note, postmenopausal women not on HT have lower estradiol levels than men. In men, estradiol was actually associated with lower cross-sectional levels of NT-proBNP. One possible explanation is that estradiol levels are higher in obese men due to increased aromatization in adipose tissue, and obesity is associated with lower levels of NT-proBNP (46, 47) . However, the inverse association between estradiol and NT-proBNP remained after adjusting for BMI. Additional studies are needed to elucidate the etiology of the relationship between estradiol and NTproBNP in men.
Strengths and limitations
The inclusion of a longitudinal design was a strength of our study, as it allowed us to assess the change in NTproBNP over time in relation to baseline sex hormone levels. Additional strengths include a large sample size, a multiethnic cohort, and the ability to evaluate six different sex hormone levels and various important confounding clinical variables.
Limitations of this study include having only a single measure of sex hormone levels at baseline. We were thus unable to analyze whether there were any associations between changes in sex hormone levels and changes in NTproBNP. MESA enrolled predominantly postmenopausal women, and we excluded the few premenopausal women for the analyses presented in this study; therefore, we were unable to examine whether relationships between sex hormone and NT-proBNP differ prior to the menopausal transition. The observational nature of our study precludes the ability to determine causality. Longitudinal analyses are limited by temporal bias from attrition. Finally, the aim of this present study was to examine the relationships of sex hormones with NT-proBNP, an important biomarker related to ventricular wall stress, volume homeostasis, and LV hypertrophy, to gain insight into sex differences in NTproBNP levels, HFpEF risk, and the female predominance of both. This complements our previous work in MESA in which we examined the relationship of sex hormones with 10-year change in cardiac structure/function (7) and aortic stiffness (9) and with incident clinical events including CVD, HF, and HFpEF (10).
Conclusions
In summary, we found that a more androgenic pattern of sex hormones was independently associated with lower NT-proBNP levels in cross-sectional analyses in men and postmenopausal women. This association may help explain sex differences in the distribution of NT-proBNP and may contribute to the NP deficiency in men relative to women. In longitudinal analyses, a more androgenic pattern of sex hormones was associated with a greater increase in NT-proBNP levels in both sexes, with a more robust association among women. This relationship may reflect a mechanism for the increased risk of CVD and HF seen in women after menopause. Additional research is needed to further explore whether longitudinal changes in NT-proBNP levels seen in our study are correlated with longitudinal changes in sex hormones. The impact of menopause on changes in NT-proBNP levels over time should also be explored. Furthermore, future studies should aim to determine whether sex hormones directly play a role in biological pathways of BNP synthesis and clearance in a causal fashion. Lastly, the dual role of NTproBNP as both a cardioprotective hormone and a biomarker of CVD and HF, as well as the role of sex hormones in delineating these processes, should be further explored. This would provide a step toward improved clinical CVD risk stratification and prognostication based on sex hormone and NT-proBNP levels.
